IQV vs MEDP Comparison: AI Score, Valuation, Performance and Upside
Compare IQVIA and Medpace by full-service vs niche CRO positioning, biotech vs pharma customer concentration, EBITDA margin structure, backlog coverage ratio, and which clinical research company offers better risk-adjusted growth.
Use this IQVIA vs Medpace comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
IQV holds the edge across 3 of 5 key metrics in this comparison. MEDP has delivered stronger 1-year price return (+31.97% vs +3.60%), though IQV has the better forward P/E setup (14.56x vs 30.93x for MEDP). Analyst consensus implies meaningfully more upside for IQV (+12.48%) than for MEDP (-5.11%).
| Metric | IQV | MEDP |
|---|---|---|
| AI score | 52.1 | 49.7 |
| AI rank | #384 | #527 |
| Latest close | $208.05 | $601.38 |
| 1M return | +12.08% | +17.28% |
| 6M return | -11.58% | -0.81% |
| 1Y return | +3.60% | +31.97% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | IQV | MEDP |
|---|---|---|
| 1Y ago | $10.45K (+4.5%) started 2025-07-25 | $13.2K (+32.0%) started 2025-07-24 |
| 5Y ago | $8.41K (-15.9%) started 2021-07-26 | $33.15K (+231.5%) started 2021-07-26 |
| 10Y ago | $28.08K (+180.8%) started 2016-07-25 | $216.4K (+2064.0%) started 2016-08-11 |
Hypothetical — past performance does not guarantee future results.
| Metric | IQV | MEDP |
|---|---|---|
| Market cap | $34.42B | $16.78B |
| Trailing P/E | 25.65 | 35.33 |
| Forward P/E | 14.56 | 30.93 |
| Price/Sales | 1.70 | 6.03 |
| EV/Revenue | 2.92 | 5.89 |
| Analyst target | $232.00 | $570.67 |
| Target upside | +12.48% | -5.11% |
| Metric | IQV | MEDP |
|---|---|---|
| Revenue growth | 8.40% | 17.20% |
| Earnings growth | 15.00% | 37.10% |
| EPS growth | +15.00% | +37.10% |
| FCF margin | +13.69% | +19.21% |
| Operating margin | 13.61% | N/A |
| Profit margin | 8.33% | 17.66% |
| ROIC proxy | 22.49% | 162.15% |
| Return on equity | 22.49% | 162.15% |
| Dividend yield | N/A | 0.00% |
| Beta | 1.20 | 1.15 |
| Debt/equity | 253.54 | 27.68 |
| Current ratio | 0.75 | 0.73 |
| Quick ratio | 0.66 | 0.66 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | IQV | MEDP |
|---|---|---|---|
| 1Y | Growth | +4.46% | +31.97% |
| CAGR | +4.47% | +32.00% | |
| Sharpe ratio | 0.19 | 0.76 | |
| Max drawdown | 35.87% | 36.61% | |
| Max daily drop | 11.88% | 22.63% | |
| Max wkly drop | 23.20% | 24.50% | |
| 5Y | Growth | -15.87% | +231.47% |
| CAGR | -3.40% | +27.12% | |
| Sharpe ratio | -0.07 | 0.62 | |
| Max drawdown | 51.52% | 42.87% | |
| Max daily drop | 11.88% | 22.63% | |
| Max wkly drop | 23.20% | 24.50% | |
| 10Y | Growth | +180.85% | +2064.02% |
| CAGR | +10.88% | +36.21% | |
| Sharpe ratio | 0.34 | 0.78 | |
| Max drawdown | 51.52% | 42.87% | |
| Max daily drop | 16.54% | 30.63% | |
| Max wkly drop | 28.34% | 28.82% |
| Category | IQV | MEDP |
|---|---|---|
| Company | IQV | MEDP |
| Sector | Healthcare | N/A |
| Industry | Diagnostics & Research | N/A |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.